KCNJ11 rs5219: Understanding the E23K Variant and Diabetes Risk
The rs5219 variant, also known as E23K, is a common genetic change in the KCNJ11 gene. It is widely studied for its association with pancreatic beta-cell function and a modest increase in the risk of developing type 2 diabetes.
What each genotype means
Typical risk profile
This genotype represents the common version of the KCNJ11 gene. Research indicates this is the baseline state against which the E23K variant is compared for type 2 diabetes risk.
This is the most common genotype in most global populations.
Increased diabetes risk
Carrying one copy of the A allele (the K variant) is associated with a statistically higher risk of developing type 2 diabetes in many populations. This variant may influence pancreatic beta-cell function, though the effect size varies significantly by ancestry and is not observed in all groups.
This heterozygous genotype is common, appearing in a significant portion of individuals across European, East Asian, and Middle Eastern populations.
Elevated diabetes risk
Carrying two copies of the A allele (the K variant) is associated with an increased susceptibility to type 2 diabetes compared to those without the variant. Some studies suggest this genotype may also be linked to secondary failure of certain diabetes medications like sulfonylureas, so please discuss your metabolic health and any medication responses with your clinician.
This homozygous genotype is less common than the heterozygous form but is found globally, with notable prevalence in various ethnic groups.
What is the rs5219 Variant?
The rs5219 variant is a single nucleotide polymorphism (SNP) located within the KCNJ11 gene. In scientific literature, this variant is frequently referred to as E23K, which describes a specific amino acid substitution where glutamic acid is replaced by lysine at position 23 of the protein. This change occurs in the NH2-terminal tail of the Kir6.2 protein, a key component of the ATP-sensitive potassium (KATP) channel. Because this channel is essential for regulating insulin release, researchers have long investigated whether this structural change alters the channel's sensitivity to ATP, the molecule that signals the pancreas to secrete insulin. While the variant is common, its presence does not guarantee any specific health outcome, as it is only one of many factors that influence metabolic health.
The Role of the KCNJ11 Gene
The KCNJ11 gene provides instructions for making the Kir6.2 protein, which forms the pore-forming subunit of the KATP channel in pancreatic beta-cells. These channels act as metabolic sensors; they monitor the levels of ATP inside the cell to determine when to release insulin into the bloodstream. When blood glucose levels rise, ATP levels increase, causing the KATP channels to close, which triggers the release of insulin. Research suggests that the E23K variant may decrease the sensitivity of these channels to ATP, potentially leading to a subtle inhibition of glucose-induced insulin secretion. While rare, severe mutations in this same gene are known to cause neonatal diabetes and congenital hyperinsulinemia, highlighting the critical importance of this gene in maintaining normal blood sugar regulation throughout life.
Research and Evidence Strength
The association between rs5219 and type 2 diabetes has been the subject of extensive meta-analyses involving tens of thousands of participants. Many studies have identified the variant as a risk factor, with the 'K' allele (often represented as the A allele in genetic databases) showing a modest but statistically significant association with increased diabetes risk. However, the evidence is nuanced; the strength of this association varies significantly by ancestry. While consistent links have been observed in Caucasian and East Asian populations, several studies have failed to replicate these findings in South Asian or other specific ethnic groups. Furthermore, some research suggests the variant may also be linked to cardiovascular risk in individuals already diagnosed with type 2 diabetes. Because of these conflicting results across different global populations, the evidence for rs5219 as a universal predictor of diabetes remains limited.
Population Frequency
The rs5219 variant is common globally, though its frequency varies by ancestry. The minor allele frequency (MAF) typically ranges from approximately 0.30 to 0.40 in many populations. For example, the risk allele frequency has been reported as low as 0.02 in some African populations and as high as 0.40 in South Asian groups. Because the variant is so common, a large portion of the global population carries at least one copy of the risk allele, which underscores why it is considered a common genetic marker rather than a rare disease-causing mutation.
Interpreting Your Genetic Information
Understanding your genotype for rs5219 provides insight into your genetic makeup, but it is not a diagnostic tool for type 2 diabetes. Because the risk associated with this variant is modest and highly dependent on your specific ancestry and environmental factors—such as diet, physical activity, and body mass index—it cannot predict whether you will develop diabetes. Genetic testing for this SNP is not currently used in routine clinical practice to guide medical treatment or prevention strategies. If you are concerned about your blood sugar levels or diabetes risk, the most effective approach is to consult with a healthcare provider. They can evaluate your overall health profile, including family history and clinical blood markers, to provide personalized guidance. Never use genetic information to make changes to your medication or health regimen without professional medical advice.
How common is this variant?
The rs5219 variant is common, with a minor allele frequency typically ranging from 0.30 to 0.40 across many global populations.
Frequently asked questions
Does having the rs5219 risk allele mean I will get diabetes?
No. The rs5219 variant is associated with a modest increase in risk, but it is not a direct cause of diabetes. Many people with the risk allele never develop the condition, and many without it do.
Is rs5219 the same as E23K?
Yes. rs5219 is the unique identifier (rsID) for the variant, while E23K describes the specific change in the protein structure where glutamic acid (E) is replaced by lysine (K) at position 23.
Should I get tested for rs5219?
There is currently no clinical recommendation to test for this variant. Diabetes risk is best assessed by a doctor through blood tests like HbA1c and fasting glucose, which measure your actual metabolic health.
Why do some studies say rs5219 is not linked to diabetes?
Genetic associations often vary by ancestry. Research has shown that the link between rs5219 and diabetes is not consistent across all ethnic groups, suggesting that other genetic or environmental factors play a larger role in different populations.
Sources & further reading
Educational information only, last refreshed 10/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5219?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in KCNJ11
This variant in the KCNJ11 potassium channel locus is widely documented to influence insulin secretion and the risk of developing type 2 diabetes.
Common polymorphism in the potassium inwardly rectifying channel subunit gene associated with insulin secretion and type 2 diabetes susceptibility.